Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
09/02/2018Race Oncology Investor Presentation February 2018Download
31/01/2018Appendix 4C - quarterlyDownload
29/01/2018Notice of Allowance for Bisantrene Patent in USDownload
29/01/2018Notice of Allowance for Bisantrene Patent in USDownload
29/01/2018Notice of Allowance for Bisantrene Patent in USDownload
29/01/2018Notice of Allowance for Bisantrene Patent in USDownload
29/01/2018Notice of Allowance for Bisantrene Patent in USDownload
29/01/2018Notice of Allowance for Bisantrene Patent in USDownload
29/01/2018Notice of Allowance for Bisantrene Patent in USDownload
24/01/2018Race Receives $170k R&D Tax Incentive RefundDownload
1  2  3  4  5  6  7  8  9  10  11  12  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2018 Race Oncology. Website By Multiplier